Various radiolabeled biomolecules for imaging of HER2 and other tumor targets have been tested as diagnostics in cancer patients, including radiolabeled trastuzumab and pertuzumab, nanobodies, antibody fragments, and other molecules, and are reviewed in detail elsewhere [39,40,41]. Here, ERBB2 is linked to cancer.